Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer.

Martin NT, Roy DG, Workenhe ST, van den Wollenberg DJM, Hoeben RC, Mossman KL, Bell JC, Bourgeois-Daigneault MC.

Sci Rep. 2019 Feb 12;9(1):1865. doi: 10.1038/s41598-018-38385-7.

2.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018. Review.

3.

Active-site mTOR inhibitors augment HSV1-dICP0 infection in cancer cells via dysregulated eIF4E/4E-BP axis.

Zakaria C, Sean P, Hoang HD, Leroux LP, Watson M, Workenhe ST, Hearnden J, Pearl D, Truong VT, Robichaud N, Yanagiya A, Tahmasebi S, Jafarnejad SM, Jia JJ, Pelin A, Diallo JS, Le Boeuf F, Bell JC, Mossman KL, Graber TE, Jaramillo M, Sonenberg N, Alain T.

PLoS Pathog. 2018 Aug 23;14(8):e1007264. doi: 10.1371/journal.ppat.1007264. eCollection 2018 Aug.

4.

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, Pol J, Bramson JL, Wan Y.

Cell Rep. 2018 Jul 17;24(3):642-654. doi: 10.1016/j.celrep.2018.06.040.

5.

Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.

van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW.

J Immunol. 2018 Jan 15;200(2):450-458. doi: 10.4049/jimmunol.1701021. Review.

6.

Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.

Workenhe ST, Ketela T, Moffat J, Cuddington BP, Mossman KL.

Oncogene. 2016 May 12;35(19):2465-74. doi: 10.1038/onc.2015.303. Epub 2015 Aug 10.

PMID:
26257065
7.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

8.

The role of oncolytic virus immunotherapies to subvert cancer immune evasion.

Workenhe ST, Verschoor ML, Mossman KL.

Future Oncol. 2015;11(4):675-89. doi: 10.2217/fon.14.254. Review.

PMID:
25686121
9.

Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.

Workenhe ST, Pol JG, Lichty BD, Cummings DT, Mossman KL.

Cancer Immunol Res. 2013 Nov;1(5):309-19. doi: 10.1158/2326-6066.CIR-13-0059-T. Epub 2013 Aug 19.

10.

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy.

Workenhe ST, Mossman KL.

Oncoimmunology. 2013 Dec 1;2(12):e27138. Epub 2013 Dec 9.

11.

Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.

Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL.

Mol Ther. 2014 Jan;22(1):123-31. doi: 10.1038/mt.2013.238. Epub 2013 Oct 9.

12.

Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.

Workenhe ST, Mossman KL.

Mol Ther. 2014 Feb;22(2):251-256. doi: 10.1038/mt.2013.220. Epub 2013 Oct 19. Review.

13.

Oncolytic bovine herpesvirus type 1 infects and kills breast tumor cells and breast cancer-initiating cells irrespective of tumor subtype.

Cuddington BP, Dyer AL, Workenhe ST, Mossman KL.

Cancer Gene Ther. 2013 May;20(5):282-9. doi: 10.1038/cgt.2013.18. Epub 2013 Apr 26.

PMID:
23618948
14.

The fight between the teleost fish immune response and aquatic viruses.

Workenhe ST, Rise ML, Kibenge MJ, Kibenge FS.

Mol Immunol. 2010 Oct;47(16):2525-36. doi: 10.1016/j.molimm.2010.06.009. Epub 2010 Aug 24. Review.

PMID:
20797792
15.

Infectious salmon anaemia virus (ISAV) isolates induce distinct gene expression responses in the Atlantic salmon (Salmo salar) macrophage/dendritic-like cell line TO, assessed using genomic techniques.

Workenhe ST, Hori TS, Rise ML, Kibenge MJ, Kibenge FS.

Mol Immunol. 2009 Sep;46(15):2955-74. doi: 10.1016/j.molimm.2009.06.015. Epub 2009 Jul 18.

PMID:
19616850
16.

Absolute quantitation of infectious salmon anaemia virus using different real-time reverse transcription PCR chemistries.

Workenhe ST, Kibenge MJ, Iwamoto T, Kibenge FS.

J Virol Methods. 2008 Dec;154(1-2):128-34. doi: 10.1016/j.jviromet.2008.08.007. Epub 2008 Sep 26.

PMID:
18789975
17.

Structural and functional studies of an IRF-7-like gene from Atlantic salmon.

Kileng O, Bergan V, Workenhe ST, Robertsen B.

Dev Comp Immunol. 2009;33(1):18-27. doi: 10.1016/j.dci.2008.07.020.

PMID:
18778729
18.

Infectious salmon anaemia virus replication and induction of alpha interferon in Atlantic salmon erythrocytes.

Workenhe ST, Kibenge MJ, Wright GM, Wadowska DW, Groman DB, Kibenge FS.

Virol J. 2008 Feb 28;5:36. doi: 10.1186/1743-422X-5-36.

19.

Demonstration of infectious salmon anaemia virus (ISAV) endocytosis in erythrocytes of Atlantic salmon.

Workenhe ST, Wadowska DW, Wright GM, Kibenge MJ, Kibenge FS.

Virol J. 2007 Jan 25;4:13.

Supplemental Content

Loading ...
Support Center